Epidemiology of Myasthenia Gravis in Denmark A Longitudinal and Comprehensive Population Survey

Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab

“…In our study 25 patients (32.89%) belonged to age group of 21–30 years, followed by 14 patients (18.42%) in 31–40 years group, followed by 11 patients (14.47%) in 51–60 years group, followed by 10 patients (13.15%) in both 41–50 years and 61–70 years groups. A bimodal distribution of age of onset was reported in previous studies, with a peak age below 40 and another peak above 50 years, which correlates with our study [ 24 ], [ 25 ].…”

Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab

“…In our study 25 patients (32.89%) belonged to age group of 21–30 years, followed by 14 patients (18.42%) in 31–40 years group, followed by 11 patients (14.47%) in 51–60 years group, followed by 10 patients (13.15%) in both 41–50 years and 61–70 years groups. A bimodal distribution of age of onset was reported in previous studies, with a peak age below 40 and another peak above 50 years, which correlates with our study [ 24 ], [ 25 ].…”

Serological and Clinical Features of Patients with Myasthenia Gravis in North Indian Population

“……”

“……”

Myasthenia Gravis in Poland: National Healthcare Database Epidemiological Study

“…Our results demonstrate an increasing prevalence of MG in Poland, which is consistent with the reports from other countries [10, 12, 16, 19, 20, 27, 34]. In our report, the clear majority of patients were older than 60 years (58.9%), and 34.1% of patients were >70 years old, in accordance with data reported by Andersen et al [6], respectively, 59 and 38%.…”

Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab

“…In our study 25 patients (32.89%) belonged to age group of 21–30 years, followed by 14 patients (18.42%) in 31–40 years group, followed by 11 patients (14.47%) in 51–60 years group, followed by 10 patients (13.15%) in both 41–50 years and 61–70 years groups. A bimodal distribution of age of onset was reported in previous studies, with a peak age below 40 and another peak above 50 years, which correlates with our study [ 24 ], [ 25 ].…”

Serological and Clinical Features of Patients with Myasthenia Gravis in North Indian Population

“……”

“……”

Myasthenia Gravis in Poland: National Healthcare Database Epidemiological Study

“…Our results demonstrate an increasing prevalence of MG in Poland, which is consistent with the reports from other countries [10, 12, 16, 19, 20, 27, 34]. In our report, the clear majority of patients were older than 60 years (58.9%), and 34.1% of patients were >70 years old, in accordance with data reported by Andersen et al [6], respectively, 59 and 38%.…”

Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab

“…In our study 25 patients (32.89%) belonged to age group of 21–30 years, followed by 14 patients (18.42%) in 31–40 years group, followed by 11 patients (14.47%) in 51–60 years group, followed by 10 patients (13.15%) in both 41–50 years and 61–70 years groups. A bimodal distribution of age of onset was reported in previous studies, with a peak age below 40 and another peak above 50 years, which correlates with our study [ 24 ], [ 25 ].…”

Serological and Clinical Features of Patients with Myasthenia Gravis in North Indian Population

“……”

“……”

Myasthenia Gravis in Poland: National Healthcare Database Epidemiological Study

“…Our results demonstrate an increasing prevalence of MG in Poland, which is consistent with the reports from other countries [10, 12, 16, 19, 20, 27, 34]. In our report, the clear majority of patients were older than 60 years (58.9%), and 34.1% of patients were >70 years old, in accordance with data reported by Andersen et al [6], respectively, 59 and 38%.…”